<DOC>
	<DOCNO>NCT01769235</DOCNO>
	<brief_summary>The objective study compare safety efficacy profile Taro Pharmaceutical Inc. 's Clindamycin Phosphate Benzoyl Peroxide Gel 1.2 % /2.5 % Acanya® ( Clindamycin Phosphate Benzoyl Peroxide ) Gel , 1.2 % /2.5 % demonstrate superior efficacy two active formulation vehicle treatment acne vulgaris .</brief_summary>
	<brief_title>Study Comparing Clindamycin Phosphate Benzoyl Peroxide Gel Acanya® Gel Both Vehicle Control Treatment Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Be willing able provide write informed consent/assent study . Be 12 40 year age , inclusive . A subject may either sex race/ethnicity . Have clinical diagnosis facial acne vulgaris 25 great noninflammatory lesion 20 great inflammatory lesion 2 nodulocystic lesion . Have baseline Investigator 's Global Assessment acne severity grade 2 , 3 4 severity scale 0 4 . Be willing able understand comply requirement study , apply study medication instruct , refrain use topical acne medication topical antibiotic 12week treatment period , return require treatment period visit , comply therapy prohibition , able complete study . Be general good health free clinically significant disease , acne vulgaris , might interfere study evaluation . Female subject childbearing potential must negative urine pregnancy test amd must willing use medically accept method contraception study . Presence 2 facial nodulocystic lesion ( i.e. , nodule cyst ) . Current diagnosis acne conglobata , acne fulminans , secondary acne . Presence active cystic acne , polycystic ovarian syndrome . History presence Crohn 's disease , ulcerative colitis , regional enteritis , antibioticassociated colitis . Presence facial skin condition might interfere acne vulgaris diagnosis and/or assessment . Excessive facial hair would interfere diagnosis assessment acne vulgaris . History unresponsiveness topical clindamycin phosphate and/or benzoyl peroxide therapy . Start change dose estrogens hormonal treatment 3 month prior baseline throughout study . Use medicate makeup throughout study significant change use consumer product within 30 day study entry throughout study . Use follow treatment recently indicate washout period prior visit 1/day 1 ; need intent continue use follow treatment study : oral retinoids therapeutic Vitamin A supplement great 10,000 units/day ; systemic steroid ; systemic antibiotic ; systemic treatment acne vulgaris ; systemic antiinflammatory immunosuppressive agent ( NSAID use allow asneeded basis 7 day consecutive use , low dose aspirin allow stable dose least 30 day ) ; Spironolactone ; use face cryodestruction chemodestruction , dermabrasion , photodynamic therapy , acne surgery , intralesional steroid , xray therapy ; topical retinoids ; topical steroid ; topical antiacne medication ; topical antiinflammatory agent ; topical antibiotic ; medicate cleanser ; use tan booth , sun lamp , sunbathe excessive exposure sun ; antipruritic , include antihistamine . History hypersensitivity allergy clindamycin phosphate , benzoyl peroxide , /or ingredient study medication . Females pregnant , breastfeeding , intend become pregnant study , agree use acceptable form birth control study . Consumption excessive alcohol , abuse drug , condition could compromise subject 's ability comply study requirement . Any clinically significant condition situation acne vulgaris would interfere study evaluation optimal participation . Use investigational drug within 30 day prior visit 1/day 1 . Participation clinical study 30 day prior sign inform consent form . Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Acne Vulgaris</keyword>
	<keyword>Clindamycin Phosphate Benzoyl Peroxide Gel</keyword>
	<keyword>Acanya® Gel</keyword>
</DOC>